What Compass Pathways’ Phase 3 trial results could mean for patients with depression.

If you live with depression — especially the kind that hasn't responded well to medication or therapy — there's news worth knowing about.

In February of 2026, Compass Pathways announced that its second Phase 3 clinical trial of psilocybin therapy hit its primary endpoint. Their drug, COMP360 — a synthetic, pharmaceutical-grade form of psilocybin (the active compound in psilocybin mushrooms) — was tested in adults with treatment-resistant depression. People who received the active 25 mg dose showed a highly statistically significant drop in depression symptoms compared with the control group.

This was the second of two large trials. Both succeeded. And the company has now begun the process of seeking FDA approval, with the goal of filing later this year.

If approved, COMP360 would become the first FDA-approved psilocybin-based treatment for depression in the United States. That's not a small thing.

I want to talk about what these results actually mean, because the headlines are easy to either over-believe or dismiss — and the truth is more interesting than either.

Why This Matters for Treatment-Resistant Depression

Treatment-resistant depression — sometimes called TRD — is a clinical term for depression that hasn't responded adequately to two or more conventional antidepressant treatments.

If you're living in that category, you already know what the experience is like. You've tried things. You've taken the medications. You've shown up for therapy. And you're still sitting with a kind of heaviness that the standard tools haven't been able to lift.

For decades, the options for TRD have been limited. New conventional antidepressants tend to be small variations on existing ones. Some people find ECT helpful. Ketamine and esketamine (Spravato) opened a real door. But the menu has remained narrow.

What makes the Compass results meaningful is that psilocybin doesn't appear to work like a conventional antidepressant. It doesn't ask you to take a pill every day for years. The trial protocol involved a small number of supervised sessions, with structured psychological support around them — and the symptom reduction held for weeks afterward.

That's a fundamentally different shape of treatment.

Three Things the Research Suggests

A few pieces stand out from the Phase 3 data and the earlier studies:

Faster relief. Conventional antidepressants typically take several weeks to begin working — and that's if they work at all. In multiple psilocybin studies, people have seen meaningful symptom reduction within days of a session. For someone in acute despair, the difference between six weeks and six days can be enormous.

Effects that last. In earlier trials, the benefits from one or a small number of psilocybin sessions persisted for months. This contrasts sharply with daily medication, which typically requires continuous dosing to maintain its effect. We're still learning about long-term durability, but the early signals are different from what we see with traditional pharmacotherapy.

A different model of care. If approved, COMP360 will not be a take-home prescription. The treatment model involves clinical setting, psychological preparation before the session, supervised dosing, and integration therapy afterward. The medicine is part of the treatment — but not the whole of it. The structured psychological support is intrinsic to how it works.

This last point is important, and it's one I care about deeply. The research doesn't suggest that psilocybin alone heals depression. It suggests that psilocybin within a structured therapeutic frame — with preparation, support, and integration — produces the outcomes we're seeing.

The Broader Picture

Compass isn't the only company working in this space.

Cybin is developing CYB003, a modified version of psilocybin currently in Phase 3 trials for major depressive disorder. MindMed has reported positive Phase 3 results on a single supervised dose of MM120 — an LSD-derived compound — for generalized anxiety disorder.

Across the field, dozens of clinical programs are now targeting treatment-resistant depression, major depressive disorder, PTSD, anxiety disorders, and substance use disorders. After decades of incremental innovation in psychiatry, this looks more like a real shift in direction.

That doesn't mean every program will succeed, or that approval will happen quickly. The FDA has its own process, and they will be looking carefully at safety, durability, and how the treatment actually performs in real-world conditions. But the ground is moving.

What I Want You to Take From This

If you're someone who has been living with depression that traditional treatments haven't fully addressed, here's what I'd want you to hear:

There may be more options on the way than there have been in a long time. The shape of psychiatric care for depression may genuinely change in the next few years.

But this isn't a "wait and see" situation, either. If you're struggling now, there are already supported options available — ketamine-assisted psychotherapy is the closest cousin to what's being studied with psilocybin, and it's available legally today within a proper clinical container. Depth-oriented and somatic therapies, on their own, also reach places that surface-level interventions don't.

The bigger truth underneath the headlines is this: we are moving away from a model where depression gets managed with a daily pill toward a model where depression gets treated — through structured experiences, psychological support, and the kind of work that helps a person actually become well rather than just less symptomatic

That's a meaningful shift. And whatever the FDA ultimately decides about COMP360, the direction of care is worth paying attention to.

If you're in California and you'd like to talk about what's available right now — including KAP — I'd be glad to hear from you. You can book a free consultation here.